Skip to content

The effects of melatonin versus placebo on post-operative delirium (POD) in hip fracture patients – a randomized double-blind trial

The effects of melatonin versus placebo on post-operative delirium (POD) in hip fracture patients – a randomized double-blind trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23033
Enrollment
175
Registered
2008-03-17
Start date
2008-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melatonin, delirium, prevention, hipfractures Melatonine, delirium, preventie, heupfracturen

Interventions

After informed consent and after surgical repair of the hip fracture, patients are randomized to receive melatonin 3 mg or placebo in the evening with a maximum of 5 days. After reaching g the primar

Sponsors

S.E. de Rooij / Academic Medical Centre Amsterdam Academic Medical Center Meibergdreef 9 1105 AZ Amsterdam The Netherlands Tel. (31)205665991 Fax (31)205669325
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 65 yrs or older 2. Unplanned surgical repair of hip or femoral fracture 3. Patients must be willing and medically able to receive therapy according to the protocol for the duration of the study

Exclusion criteria

Exclusion criteria: 1. Age: under 65 yrs 2. Delirium:pre-operative

Design outcomes

Primary

MeasureTime frame
Primary endpoint will be the occurrence of POD diagnosed with the Confusion Assessement Method (CAM-score) within 5 days after surgery.

Secondary

MeasureTime frame
1. Whether visual assessment of SPECT scans may reveal perfusion abnormalities in frontal or parietal cerebral perfusion abnormalities in patients with and without POD using placebo and in (non)-delirious patients using melatonin. 2. Differences in plasma melatonin concentrations in delirious and non-delirious patients using placebo and in patients using melatonin 3. Severity and duration of POD in placebo and melatonin group 4. Both hospital and post-discharge complications in (non) delirious patients using placebo and melatonin

Contacts

Public ContactH.E. Oosten, van

Academic Medical Center Meibergdreef 9

hvanoosten@gmail.com(31)205665991

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)